| Year |
Citation |
Score |
| 2024 |
Murray JE, Valli E, Milazzo G, Mayoh C, Gifford AJ, Fletcher JI, Xue C, Jayatilleke N, Salehzadeh F, Gamble LD, Rouaen JRC, Carter DR, Forgham H, Sekyere EO, Keating J, ... Koster J, et al. The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis. Nature Communications. 15: 5585. PMID 38992040 DOI: 10.1038/s41467-024-49871-0 |
0.301 |
|
| 2024 |
Ekstrom TL, Hussain S, Bedekovics T, Ali A, Paolini L, Mahmood H, Rosok RM, Koster J, Johnsen SA, Galardy PJ. USP44 overexpression drives a MYC-like gene expression program in neuroblastoma through epigenetic reprogramming. Molecular Cancer Research : McR. PMID 38775808 DOI: 10.1158/1541-7786.MCR-23-0454 |
0.317 |
|
| 2023 |
van Gerven MR, Schild L, van Arkel J, Koopmans B, Broeils LA, Meijs LAM, van Oosterhout R, van Noesel MM, Koster J, van Hooff SR, Molenaar JJ, van den Boogaard ML. Two opposing gene expression patterns within ATRX aberrant neuroblastoma. Plos One. 18: e0289084. PMID 37540673 DOI: 10.1371/journal.pone.0289084 |
0.306 |
|
| 2023 |
Okonechnikov K, Federico A, Schrimpf D, Sievers P, Sahm F, Koster J, Jones DTW, von Deimling A, Pfister SM, Kool M, Korshunov A. Comparison of transcriptome profiles between medulloblastoma primary and recurrent tumors uncovers novel variance effects in relapses. Acta Neuropathologica Communications. 11: 7. PMID 36635768 DOI: 10.1186/s40478-023-01504-1 |
0.331 |
|
| 2021 |
Westerhout EM, Hamdi M, Stroeken P, Nowakowska NE, Lakeman A, van Arkel J, Hasselt NE, Bleijlevens B, Akogul N, Haneveld F, Chan A, van Sluis P, Zwijnenburg D, Volckmann R, van Noesel CJ, ... ... Koster J, et al. Mesenchymal type neuroblastoma cells escape ALK inhibitors. Cancer Research. PMID 34853072 DOI: 10.1158/0008-5472.CAN-21-1621 |
0.313 |
|
| 2020 |
Bruggeman JW, Irie N, Lodder P, van Pelt AMM, Koster J, Hamer G. Tumors Widely Express Hundreds of Embryonic Germline Genes. Cancers. 12. PMID 33348709 DOI: 10.3390/cancers12123812 |
0.31 |
|
| 2020 |
Meel MH, de Gooijer MC, Metselaar DS, Sewing ACP, Zwaan K, Waranecki P, Breur M, Buil LCM, Lagerweij T, Wedekind LE, Twisk JWR, Koster J, Hashizume R, Raabe EH, Montero-Carcaboso A, et al. Combined therapy of AXL and HDAC inhibition reverses mesenchymal transition in diffuse intrinsic pontine glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32165429 DOI: 10.1158/1078-0432.Ccr-19-3538 |
0.343 |
|
| 2020 |
Dijk F, Veenstra VL, Soer EC, Dings MPG, Zhao L, Halfwerk JB, Hooijer GK, Damhofer H, Marzano M, Steins A, Waasdorp C, Busch OR, Besselink MG, Tol JA, Welling L, ... ... Koster J, et al. Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classification systems. Scientific Reports. 10: 337. PMID 31941932 DOI: 10.1038/S41598-019-56826-9 |
0.38 |
|
| 2019 |
Nederlof I, De Bortoli D, Bareche Y, Nguyen B, de Maaker M, Hooijer GKJ, Buisseret L, Kok M, Smid M, Van den Eynden GGGM, Brinkman AB, Hudecek J, Koster J, Sotiriou C, Larsimont D, et al. Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. Breast Cancer Research : Bcr. 21: 151. PMID 31878981 DOI: 10.1186/S13058-019-1239-4 |
0.316 |
|
| 2019 |
Lambo S, Gröbner SN, Rausch T, Waszak SM, Schmidt C, Gorthi A, Romero JC, Mauermann M, Brabetz S, Krausert S, Buchhalter I, Koster J, Zwijnenburg DA, Sill M, Hübner JM, et al. The molecular landscape of ETMR at diagnosis and relapse. Nature. PMID 31802000 DOI: 10.1038/S41586-019-1815-X |
0.321 |
|
| 2019 |
Metselaar DS, Meel MH, Benedict B, Waranecki P, Koster J, Kaspers GJL, Hulleman E. Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin. Ebiomedicine. PMID 31735550 DOI: 10.1016/J.Ebiom.2019.10.062 |
0.307 |
|
| 2019 |
Avitabile M, Succoio M, Testori A, Cardinale A, Vaksman Z, Lasorsa VA, Cantalupo S, Esposito M, Cimmino F, Montella A, Formicola D, Koster J, Andreotti V, Ghiorzo P, Romano MF, et al. Neural crest-derived tumor neuroblastoma and melanoma share 1p13.2 as susceptibility locus that shows a long-range interaction with the SLC16A1 gene. Carcinogenesis. PMID 31605138 DOI: 10.1093/Carcin/Bgz153 |
0.398 |
|
| 2019 |
Meel MH, Guillén Navarro M, de Gooijer MC, Metselaar DS, Waranecki P, Breur M, Lagerweij T, Wedekind LE, Koster J, van de Wetering MD, Schouten-van Meeteren N, Aronica E, van Tellingen O, Bugiani M, Phoenix TN, et al. MEK/MELK inhibition and blood-brain barrier-deficiencies in atypical teratoid/rhabdoid tumors. Neuro-Oncology. PMID 31504799 DOI: 10.1093/Neuonc/Noz151 |
0.362 |
|
| 2019 |
Lange I, Koster J, Koomoa DT. Calcium signaling regulates fundamental processes involved in Neuroblastoma progression. Cell Calcium. 82: 102052. PMID 31306997 DOI: 10.1016/J.Ceca.2019.06.006 |
0.333 |
|
| 2019 |
Georgescu C, Corbin JM, Thibivilliers S, Webb ZD, Zhao YD, Koster J, Fung KM, Asch AS, Wren JD, Ruiz-Echevarría MJ. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer. Bmc Cancer. 19: 423. PMID 31060542 DOI: 10.1186/S12885-019-5592-6 |
0.355 |
|
| 2019 |
Koster J, Plasterk RHA. A library of Neo Open Reading Frame peptides (NOPs) as a sustainable resource of common neoantigens in up to 50% of cancer patients. Scientific Reports. 9: 6577. PMID 31036835 DOI: 10.1038/S41598-019-42729-2 |
0.322 |
|
| 2019 |
Savci-Heijink CD, Halfwerk H, Koster J, Horlings HM, Vijver MJvd. A specific gene expression signature for visceral organ metastasis in breast cancer Bmc Cancer. 19: 333. PMID 30961553 DOI: 10.1186/S12885-019-5554-Z |
0.323 |
|
| 2019 |
van Groningen T, Akogul N, Westerhout EM, Chan A, Hasselt NE, Zwijnenburg DA, Broekmans M, Stroeken P, Haneveld F, Hooijer GKJ, Savci-Heijink CD, Lakeman A, Volckmann R, van Sluis P, Valentijn LJ, ... Koster J, et al. A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma. Nature Communications. 10: 1530. PMID 30948783 DOI: 10.1038/S41467-019-09470-W |
0.343 |
|
| 2019 |
Karpus ON, Westendorp BF, Vermeulen JLM, Meisner S, Koster J, Muncan V, Wildenberg ME, van den Brink GR. Colonic CD90+ Crypt Fibroblasts Secrete Semaphorins to Support Epithelial Growth. Cell Reports. 26: 3698-3708.e5. PMID 30917322 DOI: 10.1016/J.Celrep.2019.02.101 |
0.31 |
|
| 2019 |
Herold S, Kalb J, Büchel G, Ade CP, Baluapuri A, Xu J, Koster J, Solvie D, Carstensen A, Klotz C, Rodewald S, Schülein-Völk C, Dobbelstein M, Wolf E, Molenaar J, et al. Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase. Nature. PMID 30894746 DOI: 10.1038/S41586-019-1030-9 |
0.352 |
|
| 2019 |
Savci-Heijink CD, Halfwerk H, Hooijer GKJ, Koster J, Horlings HM, Meijer SL, Vijver MJvd. Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior. Breast Cancer Research and Treatment. 174: 649-659. PMID 30610490 DOI: 10.1007/S10549-018-05089-5 |
0.393 |
|
| 2019 |
Versteeg R, Valentijn L, Koster J, Groningen Tv, Hamdi M, Westerhout E, Nes Jv. Abstract SY24-02: Neuroblastoma: A developmental twist Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Sy24-02 |
0.422 |
|
| 2019 |
Corbin JM, Georgescu C, Thibivilliers S, Webb Z, Zhao Y, Koster J, Fung K, Asch A, Wren J, Ruiz-Echevarria M. Abstract 3152: A tumor suppressor-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer Cancer Research. 79: 3152-3152. DOI: 10.1158/1538-7445.Sabcs18-3152 |
0.396 |
|
| 2019 |
Nes Jv, Groningen Tv, Valentijn L, Zwijnenburg D, Westerhout EM, Hamdi M, Koster J, Versteeg R. Abstract 3662: Plasticity of transcriptional and epigenetic cellular states in neuroblastoma is driven by core lineage transcription factors Cancer Research. 79: 3662-3662. DOI: 10.1158/1538-7445.Am2019-3662 |
0.439 |
|
| 2019 |
Koster J, Volckmann R, Zwijnenburg D, Molenaar P, Versteeg R. Abstract 2490: R2: Genomics analysis and visualization platform Cancer Research. 79: 2490-2490. DOI: 10.1158/1538-7445.Am2019-2490 |
0.31 |
|
| 2018 |
Van den Eynden J, Umapathy G, Ashouri A, Cervantes-Madrid D, Szydzik J, Ruuth K, Koster J, Larsson E, Guan J, Palmer RH, Hallberg B. Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways. Science Signaling. 11. PMID 30459281 DOI: 10.1126/Scisignal.Aar5680 |
0.381 |
|
| 2018 |
Depuydt P, Koster J, Boeva V, Hocking TD, Speleman F, Schleiermacher G, De Preter K. Meta-mining of copy number profiles of high-risk neuroblastoma tumors. Scientific Data. 5: 180240. PMID 30375995 DOI: 10.1038/Sdata.2018.240 |
0.348 |
|
| 2018 |
Brabetz S, Leary SES, Gröbner SN, Nakamoto MW, Şeker-Cin H, Girard EJ, Cole B, Strand AD, Bloom KL, Hovestadt V, Mack NL, Pakiam F, Schwalm B, Korshunov A, Balasubramanian GP, ... ... Koster J, et al. A biobank of patient-derived pediatric brain tumor models. Nature Medicine. PMID 30349086 DOI: 10.1038/S41591-018-0207-3 |
0.405 |
|
| 2018 |
Braekeveldt N, von Stedingk K, Fransson S, Martinez-Monleon A, Lindgren D, Axelson H, Levander F, Willforss J, Hansson K, Øra I, Backman T, Börjesson A, Beckman S, Esfandyari J, Berbegall AP, ... ... Koster J, et al. Patient-derived xenograft models reveal intratumor heterogeneity and temporal stability in neuroblastoma. Cancer Research. PMID 30154149 DOI: 10.1158/0008-5472.Can-18-0527 |
0.358 |
|
| 2018 |
Cimmino F, Avitabile M, Diskin SJ, Vaksman Z, Pignataro P, Formicola D, Cardinale A, Testori A, Koster J, de Torres C, Devoto M, Maris JM, Iolascon A, Capasso M. Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor-suppressor. International Journal of Cancer. PMID 30132831 DOI: 10.1002/Ijc.31822 |
0.321 |
|
| 2018 |
Eleveld TF, Schild L, Koster J, Zwijnenburg DA, Alles LK, Ebus ME, Volckmann R, Tytgat GAM, van Sluis P, Versteeg R, Molenaar JJ. RAS-MAPK pathway-driven tumor progression is associated with loss of CIC and other genomic aberrations in neuroblastoma. Cancer Research. PMID 30115695 DOI: 10.1158/0008-5472.Can-18-1045 |
0.35 |
|
| 2018 |
Meel MH, de Gooijer MC, Guillén Navarro M, Waranecki P, Breur M, Buil L, Wedekind LE, Twisk JWR, Koster J, Hashizume R, Raabe EH, Montero Carcaboso A, Bugiani M, van Tellingen O, van Vuurden DG, et al. MELK inhibition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30061363 DOI: 10.1158/1078-0432.Ccr-18-0924 |
0.301 |
|
| 2018 |
Bruggeman JW, Koster J, Lodder P, Repping S, Hamer G. Massive expression of germ cell-specific genes is a hallmark of cancer and a potential target for novel treatment development. Oncogene. PMID 29907769 DOI: 10.1038/S41388-018-0357-2 |
0.425 |
|
| 2018 |
Agarwal S, Milazzo G, Rajapakshe K, Bernardi R, Chen Z, Barberi E, Koster J, Perini G, Coarfa C, Shohet JM. MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma. Oncotarget. 9: 20323-20338. PMID 29755654 DOI: 10.18632/Oncotarget.24859 |
0.337 |
|
| 2018 |
Ménard M, Costechareyre C, Ichim G, Blachier J, Neves D, Jarrosson-Wuilleme L, Depping R, Koster J, Saintigny P, Mehlen P, Tauszig-Delamasure S. Hey1- and p53-dependent TrkC proapoptotic activity controls neuroblastoma growth. Plos Biology. 16: e2002912. PMID 29750782 DOI: 10.1371/Journal.Pbio.2002912 |
0.357 |
|
| 2018 |
Trumpi K, Frenkel N, Peters T, Korthagen NM, Jongen JMJ, Raats D, van Grevenstein H, Backes Y, Moons LM, Lacle MM, Koster J, Zwijnenburg D, Borel Rinkes IHM, Kranenburg O. Macrophages induce "budding" in aggressive human colon cancer subtypes by protease-mediated disruption of tight junctions. Oncotarget. 9: 19490-19507. PMID 29731961 DOI: 10.18632/Oncotarget.24626 |
0.41 |
|
| 2018 |
Rajbhandari P, Lopez G, Capdevila C, Salvatori B, Yu J, Rodriguez-Barrueco R, Martinez D, Yarmarkovich M, Weichert-Leahey N, Abraham BJ, Alvarez MJ, Iyer A, Harenza JL, Oldridge D, De Preter K, ... Koster J, et al. Cross-cohort analysis identifies a TEAD4 ↔ MYCN positive-feedback loop as the core regulatory element of high-risk neuroblastoma. Cancer Discovery. PMID 29510988 DOI: 10.1158/2159-8290.Cd-16-0861 |
0.367 |
|
| 2018 |
Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, Johann PD, Balasubramanian GP, Segura-Wang M, Brabetz S, Bender S, Hutter B, Sturm D, Pfaff E, Hübschmann D, ... ... Koster J, et al. The landscape of genomic alterations across childhood cancers. Nature. PMID 29489754 DOI: 10.1038/Nature25480 |
0.323 |
|
| 2018 |
Groß AS, Schulz C, Kolb J, Koster J, Wehner S, Czaplinski S, Khilan A, Rohrer H, Harter PN, Klingebiel T, Langer JD, Geerts D, Schulte D. Tumorigenic and anti-proliferative properties of the TALE-transcription factors MEIS2D and MEIS2A in neuroblastoma. Cancer Research. PMID 29382709 DOI: 10.1158/0008-5472.Can-17-1860 |
0.437 |
|
| 2018 |
Schultz CR, Geerts D, Mooney M, El-Khawaja R, Koster J, Bachmann AS. Synergistic drug combination GC7/DFMO suppresses hypusine/spermidine-dependent eIF5A activation and induces apoptotic cell death in neuroblastoma. The Biochemical Journal. PMID 29295892 DOI: 10.1042/Bcj20170597 |
0.346 |
|
| 2018 |
Versteeg R, Groningen Tv, Koster J, Valentijn LJ, Nes Jv. Abstract IA10: Neuroblastoma is a biphasic tumor Cancer Research. 78. DOI: 10.1158/1538-7445.Pedca17-Ia10 |
0.419 |
|
| 2018 |
Brabetz S, Groebner SN, Jaeger N, Milde T, Ecker J, Selt F, Witt O, Rusert JM, Koster J, Leary SE, Li X, Wechsler-Reya RJ, Olson JM, Pfister SM, Kool M. PCLN-05. A BIOBANK OF PATIENT-DERIVED MOLECULARLY CHARACTERIZED ORTHOTOPIC PEDIATRIC BRAIN TUMOR MODELS FOR PRECLINICAL RESEARCH Neuro-Oncology. 20: i155-i155. DOI: 10.1093/Neuonc/Noy059.574 |
0.3 |
|
| 2017 |
Savci-Heijink CD, Halfwerk H, Koster J, Van de Vijver MJ. Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer. Bmc Cancer. 17: 755. PMID 29132326 DOI: 10.1186/S12885-017-3691-9 |
0.352 |
|
| 2017 |
Russo R, Cimmino F, Pezone L, Manna F, Avitabile M, Langella C, Koster J, Casale F, Raia M, Viola G, Fischer M, Iolascon A, Capasso M. Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients. Carcinogenesis. PMID 28968651 DOI: 10.1093/Carcin/Bgx077 |
0.382 |
|
| 2017 |
Meel MH, Sewing ACP, Waranecki P, Metselaar DS, Wedekind LE, Koster J, van Vuurden DG, Kaspers GJL, Hulleman E. Culture methods of diffuse intrinsic pontine glioma cells determine response to targeted therapies. Experimental Cell Research. PMID 28947132 DOI: 10.1016/J.Yexcr.2017.09.032 |
0.321 |
|
| 2017 |
Northcott PA, Buchhalter I, Morrissy AS, Hovestadt V, Weischenfeldt J, Ehrenberger T, Gröbner S, Segura-Wang M, Zichner T, Rudneva VA, Warnatz HJ, Sidiropoulos N, Phillips AH, Schumacher S, Kleinheinz K, ... ... Koster J, et al. The whole-genome landscape of medulloblastoma subtypes. Nature. 547: 311-317. PMID 28726821 DOI: 10.1038/Nature22973 |
0.371 |
|
| 2017 |
van Groningen T, Koster J, Valentijn LJ, Zwijnenburg DA, Akogul N, Hasselt NE, Broekmans M, Haneveld F, Nowakowska NE, Bras J, van Noesel CJM, Jongejan A, van Kampen AH, Koster L, Baas F, et al. Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nature Genetics. PMID 28650485 DOI: 10.1038/Ng.3899 |
0.432 |
|
| 2017 |
Bate-Eya LT, Gierman HJ, Ebus ME, Koster J, Caron HN, Versteeg R, Dolman ME, Molenaar JJ. Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity. European Journal of Cancer (Oxford, England : 1990). 75: 63-72. PMID 28214660 DOI: 10.1016/J.Ejca.2016.12.019 |
0.387 |
|
| 2017 |
Hakkert A, Ebus ME, Versteeg R, Huib CN, Koster J, Molenaar JJ. Abstract A26: High frequency of Cytosine to Adenine mutations in neuroblastoma correlates with genomic aberrations in 8-Oxo-Guanine repair pathway Molecular Cancer Research. 15. DOI: 10.1158/1557-3125.Dnarepair16-A26 |
0.368 |
|
| 2017 |
Nes Jv, Groningen Tv, Valentijn LJ, Zwijnenburg D, Molenaar JJ, Westerman BA, Westerhout EM, Hamdi M, Tytgat GA, Koster J, Versteeg R. Abstract 3876: Active enhancers delineate intra-tumor heterogeneity of developmental states in neuroblastoma Cancer Research. 77: 3876-3876. DOI: 10.1158/1538-7445.Am2017-3876 |
0.322 |
|
| 2016 |
Vella S, Tavanti E, Hattinger CM, Fanelli M, Versteeg R, Koster J, Picci P, Serra M. Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells. Plos One. 11: e0166233. PMID 27898692 DOI: 10.1371/Journal.Pone.0166233 |
0.336 |
|
| 2016 |
Matas-Rico E, van Veen M, Leyton-Puig D, van den Berg J, Koster J, Kedziora KM, Molenaar B, Weerts MJ, de Rink I, Medema RH, Giepmans BN, Perrakis A, Jalink K, Versteeg R, Moolenaar WH. Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical Outcome. Cancer Cell. PMID 27693046 DOI: 10.1016/J.Ccell.2016.08.016 |
0.379 |
|
| 2016 |
Fabian J, Opitz D, Althoff K, Lodrini M, Hero B, Volland R, Beckers A, Preter K, Decock A, Patil N, Abba M, Kopp-Schneider A, Astrahantseff K, Wünschel J, Pfeil S, ... ... Koster J, et al. MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma. Oncotarget. PMID 27572323 DOI: 10.18632/Oncotarget.11662 |
0.339 |
|
| 2016 |
Eberhardt A, Hansen JN, Koster J, Lotta LT, Wang S, Livingstone E, Qian K, Valentijn LJ, Zheng YG, Schor NF, Li X. Protein arginine methyltransferase 1 is a novel regulator of MYCN in neuroblastoma. Oncotarget. PMID 27571165 DOI: 10.18632/Oncotarget.11556 |
0.391 |
|
| 2016 |
Middelbeek J, Vrenken K, Visser D, Lasonder E, Koster J, Jalink K, Clark K, van Leeuwen FN. The TRPM7 interactome defines a cytoskeletal complex linked to neuroblastoma progression. European Journal of Cell Biology. PMID 27402209 DOI: 10.1016/J.Ejcb.2016.06.008 |
0.41 |
|
| 2016 |
Bate-Eya LT, den Hartog IJ, van der Ploeg I, Schild L, Koster J, Santo EE, Westerhout EM, Versteeg R, Caron HN, Molenaar JJ, Dolman ME. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. Oncotarget. PMID 27056887 DOI: 10.18632/Oncotarget.8547 |
0.354 |
|
| 2016 |
Vellinga TT, den Uil S, Rinkes IH, Marvin D, Ponsioen B, Alvarez-Varela A, Fatrai S, Scheele C, Zwijnenburg DA, Snippert H, Vermeulen L, Medema JP, Stockmann HB, Koster J, Fijneman RJ, et al. Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion. Oncogene. PMID 26996663 DOI: 10.1038/Onc.2016.60 |
0.45 |
|
| 2016 |
Savci-Heijink CD, Halfwerk H, Koster J, van de Vijver MJ. A novel gene expression signature for bone metastasis in breast carcinomas. Breast Cancer Research and Treatment. 156: 249-59. PMID 26965286 DOI: 10.1007/S10549-016-3741-Z |
0.326 |
|
| 2016 |
Johann PD, Erkek S, Zapatka M, Kerl K, Buchhalter I, Hovestadt V, Jones DT, Sturm D, Hermann C, Segura Wang M, Korshunov A, Rhyzova M, Gröbner S, Brabetz S, Chavez L, ... ... Koster J, et al. Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell. PMID 26923874 DOI: 10.1016/J.Ccell.2016.02.001 |
0.392 |
|
| 2016 |
Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DT, Capper D, Sill M, Buchhalter I, Northcott PA, Leis I, Ryzhova M, Koelsche C, Pfaff E, Allen SJ, Balasubramanian G, ... ... Koster J, et al. New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell. 164: 1060-1072. PMID 26919435 DOI: 10.1016/J.Cell.2016.01.015 |
0.362 |
|
| 2016 |
Versteeg R, Groningen Tv, Westerman BA, Molenaar JJ, Westerhout EM, Hamdi M, Tytgat GA, Koster J, Nes Jv. Abstract PR08: Neuroblastoma is biphasic and includes classical neuroepithelial cells and chemoresistant mesenchymal cells Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-Pr08 |
0.449 |
|
| 2016 |
Koster J, Valentijn LJ, Zwijnenburg DA, Hasselt NE, Sluis PGv, Noesel MMv, George RE, Tytgat GA, Molenaar JJ, Versteeg R. Abstract PR06: TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-Pr06 |
0.431 |
|
| 2016 |
Bate-Eya LT, Hartog IJMd, Ploeg Ivd, Schild L, Koster J, Versteeg R, Caron HN, Molenaar JJ, Dolman MEM. Abstract B09: MCL-1 inhibition improves ABT199 efficacy for BCL-2-dependent neuroblastoma Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-B09 |
0.385 |
|
| 2016 |
Versteeg R, Groningen Tv, Valentijn LJ, Westerman BA, Molenaar JJ, Westerhout EM, Hamdi M, Tytgat GA, Koster J, JvN. Abstract 2453: Neuroblastoma is bi-phasic and includes classical neuro-epithelial cells and chemo-resistant mesenchymal cells Cancer Research. 76: 2453-2453. DOI: 10.1158/1538-7445.Am2016-2453 |
0.423 |
|
| 2015 |
Dolman ME, van der Ploeg I, Koster J, Bate-Eya LT, Versteeg R, Caron HN, Molenaar JJ. DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells. Plos One. 10: e0145744. PMID 26716839 DOI: 10.1371/Journal.Pone.0145744 |
0.345 |
|
| 2015 |
Best MG, Sol N, Kooi I, Tannous J, Westerman BA, Rustenburg F, Schellen P, Verschueren H, Post E, Koster J, Ylstra B, Ameziane N, Dorsman J, Smit EF, Verheul HM, et al. RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell. 28: 666-76. PMID 26525104 DOI: 10.1016/J.Ccell.2015.09.018 |
0.352 |
|
| 2015 |
Valentijn LJ, Koster J, Zwijnenburg DA, Hasselt NE, van Sluis P, Volckmann R, van Noesel MM, George RE, Tytgat GA, Molenaar JJ, Versteeg R. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nature Genetics. PMID 26523776 DOI: 10.1038/Ng.3438 |
0.354 |
|
| 2015 |
Eleveld TF, Oldridge DA, Bernard V, Koster J, Daage LC, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Né P, Michon J, Pugh TJ, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics. PMID 26121087 DOI: 10.1038/Ng.3333 |
0.363 |
|
| 2015 |
Yco LP, Geerts D, Mocz G, Koster J, Bachmann AS. Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target. Bmc Cancer. 15: 477. PMID 26093909 DOI: 10.1186/S12885-015-1447-Y |
0.385 |
|
| 2015 |
Mandriota SJ, Valentijn LJ, Lesne L, Betts DR, Marino D, Boudal-Khoshbeen M, London WB, Rougemont AL, Attiyeh EF, Maris JM, Hogarty MD, Koster J, Molenaar JJ, Versteeg R, Ansari M, et al. Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism. Oncotarget. 6: 18558-76. PMID 26053094 DOI: 10.18632/Oncotarget.4061 |
0.366 |
|
| 2015 |
Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, Wani K, Tatevossian R, Punchihewa C, Johann P, Reimand J, Warnatz HJ, Ryzhova M, Mack S, Ramaswamy V, ... ... Koster J, et al. Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell. 27: 728-43. PMID 25965575 DOI: 10.1016/J.Ccell.2015.04.002 |
0.343 |
|
| 2015 |
Fatrai S, van Schelven SJ, Ubink I, Govaert KM, Raats D, Koster J, Verheem A, Borel Rinkes IH, Kranenburg O. Maintenance of Clonogenic KIT(+) Human Colon Tumor Cells Requires Secretion of Stem Cell Factor by Differentiated Tumor Cells. Gastroenterology. 149: 692-704. PMID 25962936 DOI: 10.1053/J.Gastro.2015.05.003 |
0.381 |
|
| 2015 |
van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, van Houdt W, van Gorp J, Taylor-Weiner A, Kester L, McLaren-Douglas A, Blokker J, Jaksani S, Bartfeld S, Volckman R, ... ... Koster J, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 161: 933-45. PMID 25957691 DOI: 10.1016/J.Cell.2015.03.053 |
0.402 |
|
| 2015 |
Vellinga TT, Borovski T, de Boer VC, Fatrai S, van Schelven S, Trumpi K, Verheem A, Snoeren N, Emmink BL, Koster J, Rinkes IH, Kranenburg O. SIRT1/PGC1α-Dependent Increase in Oxidative Phosphorylation Supports Chemotherapy Resistance of Colon Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2870-9. PMID 25779952 DOI: 10.1158/1078-0432.Ccr-14-2290 |
0.372 |
|
| 2015 |
Wegert J, Ishaque N, Vardapour R, Geörg C, Gu Z, Bieg M, Ziegler B, Bausenwein S, Nourkami N, Ludwig N, Keller A, Grimm C, Kneitz S, Williams RD, Chagtai T, ... ... Koster J, et al. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. Cancer Cell. 27: 298-311. PMID 25670083 DOI: 10.1016/J.Ccell.2015.01.002 |
0.387 |
|
| 2015 |
Von Stedingk K, De Preter K, Vandesompele J, Noguera R, Øra I, Koster J, Versteeg R, Påhlman S, Lindgren D, Axelson H. Individual patient risk stratification of high-risk neuroblastomas using a two-gene score suited for clinical use International Journal of Cancer. 137: 868-877. PMID 25652004 DOI: 10.1002/Ijc.29461 |
0.348 |
|
| 2015 |
van Wezel EM, Zwijnenburg D, Zappeij-Kannegieter L, Bus E, van Noesel MM, Molenaar JJ, Versteeg R, Fiocco M, Caron HN, van der Schoot CE, Koster J, Tytgat GA. Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma. The Journal of Molecular Diagnostics : Jmd. 17: 43-52. PMID 25445214 DOI: 10.1016/J.Jmoldx.2014.09.005 |
0.353 |
|
| 2015 |
Groningen Tv, Nowakowska NE, Akogul N, Broekmans M, Bras J, Booij J, Ebus ME, Molenaar JJ, Westerhout EM, Hamdi M, Sluis Pv, Koster J, Westerman BA, Tytgat GA, Versteeg R, et al. Abstract LB-209: Neuroblastoma is biphasic with classical neuro-epithelial cells and chemoresistant mesenchymal cells controlled by PRRX1-NOTCH signaling Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-209 |
0.425 |
|
| 2014 |
Bandino A, Geerts D, Koster J, Bachmann AS. Deoxyhypusine synthase (DHPS) inhibitor GC7 induces p21/Rb-mediated inhibition of tumor cell growth and DHPS expression correlates with poor prognosis in neuroblastoma patients. Cellular Oncology (Dordrecht). 37: 387-98. PMID 25315710 DOI: 10.1007/S13402-014-0201-9 |
0.418 |
|
| 2014 |
van Keimpema M, Grüneberg LJ, Mokry M, van Boxtel R, Koster J, Coffer PJ, Pals ST, Spaargaren M. FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells. Blood. 124: 3431-40. PMID 25267198 DOI: 10.1182/Blood-2014-01-553412 |
0.362 |
|
| 2014 |
Emmink BL, Laoukili J, Kipp AP, Koster J, Govaert KM, Fatrai S, Verheem A, Steller EJ, Brigelius-Flohé R, Jimenez CR, Borel Rinkes IH, Kranenburg O. GPx2 suppression of H2O2 stress links the formation of differentiated tumor mass to metastatic capacity in colorectal cancer. Cancer Research. 74: 6717-30. PMID 25261240 DOI: 10.1158/0008-5472.Can-14-1645 |
0.379 |
|
| 2014 |
Northcott PA, Lee C, Zichner T, Stütz AM, Erkek S, Kawauchi D, Shih DJ, Hovestadt V, Zapatka M, Sturm D, Jones DT, Kool M, Remke M, Cavalli FM, Zuyderduyn S, ... ... Koster J, et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature. 511: 428-34. PMID 25043047 DOI: 10.1038/Nature13379 |
0.322 |
|
| 2014 |
Hovestadt V, Jones DT, Picelli S, Wang W, Kool M, Northcott PA, Sultan M, Stachurski K, Ryzhova M, Warnatz HJ, Ralser M, Brun S, Bunt J, Jäger N, Kleinheinz K, ... ... Koster J, et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature. 510: 537-41. PMID 24847876 DOI: 10.1038/Nature13268 |
0.366 |
|
| 2014 |
Kool M, Jones DT, Jäger N, Northcott PA, Pugh TJ, Hovestadt V, Piro RM, Esparza LA, Markant SL, Remke M, Milde T, Bourdeaut F, Ryzhova M, Sturm D, Pfaff E, ... ... Koster J, et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell. 25: 393-405. PMID 24651015 DOI: 10.1016/J.Ccr.2014.02.004 |
0.331 |
|
| 2014 |
Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stütz AM, Wang X, Gallo M, Garzia L, Zayne K, Zhang X, Ramaswamy V, Jäger N, Jones DT, Sill M, ... ... Koster J, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature. 506: 445-50. PMID 24553142 DOI: 10.1038/Nature13108 |
0.351 |
|
| 2014 |
Bate-Eya LT, Ebus ME, Koster J, den Hartog IJ, Zwijnenburg DA, Schild L, van der Ploeg I, Dolman ME, Caron HN, Versteeg R, Molenaar JJ. Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours. European Journal of Cancer (Oxford, England : 1990). 50: 628-37. PMID 24321263 DOI: 10.1016/J.Ejca.2013.11.015 |
0.353 |
|
| 2014 |
Lange I, Geerts D, Feith DJ, Mocz G, Koster J, Bachmann AS. Novel interaction of ornithine decarboxylase with sepiapterin reductase regulates neuroblastoma cell proliferation. Journal of Molecular Biology. 426: 332-46. PMID 24096079 DOI: 10.1016/J.Jmb.2013.09.037 |
0.362 |
|
| 2014 |
Eleveld TF, Schild L, Koster J, Zwijnenburg D, Ebus ME, van PS, Schulte JH, Caron HN, Versteeg R, Molenaar JJ. Abstract B41: Whole genome sequencing identifies tumor evolution events in relapse neuroblastoma Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-B41 |
0.404 |
|
| 2013 |
Jäger N, Schlesner M, Jones DT, Raffel S, Mallm JP, Junge KM, Weichenhan D, Bauer T, Ishaque N, Kool M, Northcott PA, Korshunov A, Drews RM, Koster J, Versteeg R, et al. Hypermutation of the inactive X chromosome is a frequent event in cancer. Cell. 155: 567-81. PMID 24139898 DOI: 10.1016/J.Cell.2013.09.042 |
0.329 |
|
| 2013 |
Zeilstra J, Joosten SP, Vermeulen L, Koster J, Medema JP, Versteeg R, Spaargaren M, Pals ST. CD44 expression in intestinal epithelium and colorectal cancer is independent of p53 status. Plos One. 8: e72849. PMID 24009708 DOI: 10.1371/Journal.Pone.0072849 |
0.325 |
|
| 2013 |
von Stedingk K, Koster J, Piqueras M, Noguera R, Navarro S, Påhlman S, Versteeg R, Ora I, Gisselsson D, Lindgren D, Axelson H. snoRNPs Regulate Telomerase Activity in Neuroblastoma and Are Associated with Poor Prognosis. Translational Oncology. 6: 447-57. PMID 23908688 DOI: 10.1593/Tlo.13112 |
0.395 |
|
| 2013 |
Jones DT, Hutter B, Jäger N, Korshunov A, Kool M, Warnatz HJ, Zichner T, Lambert SR, Ryzhova M, Quang DA, Fontebasso AM, Stütz AM, Hutter S, Zuckermann M, Sturm D, ... ... Koster J, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature Genetics. 45: 927-32. PMID 23817572 DOI: 10.1038/Ng.2682 |
0.409 |
|
| 2013 |
Van Nes J, Chan A, Van Groningen T, Van Sluis P, Koster J, Versteeg R. A NOTCH3 transcriptional module induces cell motility in neuroblastoma Clinical Cancer Research. 19: 3485-3494. PMID 23649002 DOI: 10.1158/1078-0432.Ccr-12-3021 |
0.441 |
|
| 2013 |
Steller EJ, Raats DA, Koster J, Rutten B, Govaert KM, Emmink BL, Snoeren N, van Hooff SR, Holstege FC, Maas C, Borel Rinkes IH, Kranenburg O. PDGFRB promotes liver metastasis formation of mesenchymal-like colorectal tumor cells. Neoplasia (New York, N.Y.). 15: 204-17. PMID 23441134 DOI: 10.1593/Neo.121726 |
0.412 |
|
| 2013 |
Yco LP, Geerts D, Koster J, Bachmann AS. PRAF2 stimulates cell proliferation and migration and predicts poor prognosis in neuroblastoma. International Journal of Oncology. 42: 1408-16. PMID 23440329 DOI: 10.3892/Ijo.2013.1836 |
0.409 |
|
| 2013 |
Koomoa DL, Geerts D, Lange I, Koster J, Pegg AE, Feith DJ, Bachmann AS. DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma. International Journal of Oncology. 42: 1219-28. PMID 23440295 DOI: 10.3892/Ijo.2013.1835 |
0.398 |
|
| 2013 |
Santo EE, Stroeken P, Sluis PV, Koster J, Versteeg R, Westerhout EM. FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma Cancer Research. 73: 2189-2198. PMID 23378341 DOI: 10.1158/0008-5472.Can-12-3767 |
0.401 |
|
| 2013 |
Bunt J, Hasselt NA, Zwijnenburg DA, Koster J, Versteeg R, Kool M. OTX2 sustains a bivalent-like state of OTX2-bound promoters in medulloblastoma by maintaining their H3K27me3 levels Acta Neuropathologica. 125: 385-394. PMID 23179372 DOI: 10.1007/S00401-012-1069-2 |
0.396 |
|
| 2013 |
Wood AC, Pugh TJ, Morozova O, Koster J, Molenaar JJ, Pineros V, Bosse KR, Perin JC, Diskin S, Diamond MA, Marra M, Meyerson M, Versteeg R, Maris JM. Abstract 3804: Rare DNA variants are enriched at the BARD1 locus and likely influence neuroblastoma susceptibility. Cancer Research. 73: 3804-3804. DOI: 10.1158/1538-7445.Am2013-3804 |
0.348 |
|
| 2013 |
Molenaar JJ, Koster J, Ebus M, Zwijnenburg DA, Sluis Pv, Lamers F, Schild L, Ploeg Ivd, Caron HN, Versteeg R. L04.05 Targeted Drug Development In Pediatric Cancer Despite A Low Frequency Of Tumor Driving Mutations Annals of Oncology. 24. DOI: 10.1093/Annonc/Mdt042.19 |
0.328 |
|
| 2013 |
Versteeg R, Groningen Tv, Molenaar J, Westerman B, Koster J, Nes Jv. Mutation spectrum and pathway signatures mark neuroblastoma cells reflecting multiple developmental stages Autonomic Neuroscience: Basic and Clinical. 177: 26. DOI: 10.1016/J.Autneu.2013.05.034 |
0.305 |
|
| 2012 |
Korshunov A, Ryzhova M, Jones DT, Northcott PA, van Sluis P, Volckmann R, Koster J, Versteeg R, Cowdrey C, Perry A, Picard D, Rosenblum M, Giangaspero F, Aronica E, Schüller U, et al. LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathologica. 124: 875-81. PMID 23161096 DOI: 10.1007/S00401-012-1068-3 |
0.395 |
|
| 2012 |
Valentijn LJ, Koster J, Haneveld F, Aissa RA, Van Sluis P, Broekmans MEC, Molenaar JJ, Van Nes J, Versteeg R. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification Proceedings of the National Academy of Sciences of the United States of America. 109: 19190-19195. PMID 23091029 DOI: 10.1073/Pnas.1208215109 |
0.437 |
|
| 2012 |
Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tönjes M, Sill M, Bender S, Kool M, Zapatka M, Becker N, Zucknick M, Hielscher T, ... ... Koster J, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 22: 425-37. PMID 23079654 DOI: 10.1016/J.Ccr.2012.08.024 |
0.323 |
|
| 2012 |
Schramm A, Schowe B, Fielitz K, Heilmann M, Martin M, Marschall T, Köster J, Vandesompele J, Vermeulen J, de Preter K, Koster J, Versteeg R, Noguera R, Speleman F, Rahmann S, et al. Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome. British Journal of Cancer. 107: 1409-17. PMID 23047593 DOI: 10.1038/Bjc.2012.391 |
0.347 |
|
| 2012 |
Molenaar JJ, Domingo-Fernández R, Ebus ME, Lindner S, Koster J, Drabek K, Mestdagh P, van Sluis P, Valentijn LJ, van Nes J, Broekmans M, Haneveld F, Volckmann R, Bray I, Heukamp L, et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nature Genetics. 44: 1199-206. PMID 23042116 DOI: 10.1038/Ng.2436 |
0.353 |
|
| 2012 |
Jones DT, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, Cho YJ, Pugh TJ, Hovestadt V, Stütz AM, Rausch T, Warnatz HJ, Ryzhova M, Bender S, Sturm D, ... ... Koster J, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature. 488: 100-5. PMID 22832583 DOI: 10.1038/Nature11284 |
0.385 |
|
| 2012 |
Lamers F, Schild L, Koster J, Speleman F, Øra I, Westerhout EM, van Sluis P, Versteeg R, Caron HN, Molenaar JJ. Identification of BIRC6 as a novel intervention target for neuroblastoma therapy. Bmc Cancer. 12: 285. PMID 22788920 DOI: 10.1186/1471-2407-12-285 |
0.434 |
|
| 2012 |
Muñoz J, Stange DE, Schepers AG, van de Wetering M, Koo BK, Itzkovitz S, Volckmann R, Kung KS, Koster J, Radulescu S, Myant K, Versteeg R, Sansom OJ, van Es JH, Barker N, et al. The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent '+4' cell markers. The Embo Journal. 31: 3079-91. PMID 22692129 DOI: 10.1038/Emboj.2012.166 |
0.351 |
|
| 2012 |
Kemper K, Versloot M, Cameron K, Colak S, De Sousa E Melo F, De Jong JH, Bleackley J, Vermeulen L, Versteeg R, Koster J, Medema JP. Mutations in the Ras-Raf axis underlie the prognostic value of CD133 in colorectal cancer Clinical Cancer Research. 18: 3132-3141. PMID 22496204 DOI: 10.1158/1078-0432.Ccr-11-3066 |
0.311 |
|
| 2012 |
Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, Ebus ME, Haneveld F, Lakeman A, Schild L, Molenaar P, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature. 483: 589-93. PMID 22367537 DOI: 10.1038/Nature10910 |
0.339 |
|
| 2012 |
Lamers F, Schild L, den Hartog IJ, Ebus ME, Westerhout EM, Ora I, Koster J, Versteeg R, Caron HN, Molenaar JJ. Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth. European Journal of Cancer (Oxford, England : 1990). 48: 3093-103. PMID 22366560 DOI: 10.1016/J.Ejca.2012.01.037 |
0.376 |
|
| 2012 |
Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, Cho YJ, Koster J, Schouten-van Meeteren A, van Vuurden D, Clifford SC, Pietsch T, von Bueren AO, Rutkowski S, McCabe M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathologica. 123: 473-84. PMID 22358457 DOI: 10.1007/S00401-012-0958-8 |
0.329 |
|
| 2012 |
Rausch T, Jones DT, Zapatka M, Stütz AM, Zichner T, Weischenfeldt J, Jäger N, Remke M, Shih D, Northcott PA, Pfaff E, Tica J, Wang Q, Massimi L, Witt H, ... ... Koster J, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 148: 59-71. PMID 22265402 DOI: 10.1016/J.Cell.2011.12.013 |
0.376 |
|
| 2012 |
Gawecka JE, Geerts D, Koster J, Caliva MJ, Sulzmaier FJ, Opoku-Ansah J, Wada RK, Bachmann AS, Ramos JW. PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma. International Journal of Cancer. 131: 1556-68. PMID 22213050 DOI: 10.1002/Ijc.27415 |
0.424 |
|
| 2012 |
Lamers F, Schild L, Koster J, Versteeg R, Caron HN, Molenaar JJ. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. European Journal of Cancer (Oxford, England : 1990). 48: 763-71. PMID 22088485 DOI: 10.1016/J.Ejca.2011.10.012 |
0.374 |
|
| 2012 |
Molenaar JJ, Koster J, Ebus ME, van Sluis P, Westerhout EM, de Preter K, Gisselsson D, Øra I, Speleman F, Caron HN, Versteeg R. Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. Genes, Chromosomes & Cancer. 51: 10-9. PMID 22034077 DOI: 10.1002/Gcc.20926 |
0.43 |
|
| 2012 |
Bunt J, Hasselt NE, Zwijnenburg DA, Hamdi M, Koster J, Versteeg R, Kool M. OTX2 directly activates cell cycle genes and inhibits differentiation in medulloblastoma cells. International Journal of Cancer. 131: E21-32. PMID 21964830 DOI: 10.1002/Ijc.26474 |
0.423 |
|
| 2012 |
Santo EE, Ebus ME, Koster J, Schulte JH, Lakeman A, van Sluis P, Vermeulen J, Gisselsson D, Øra I, Lindner S, Buckley PG, Stallings RL, Vandesompele J, Eggert A, Caron HN, et al. Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. Oncogene. 31: 1571-81. PMID 21860421 DOI: 10.1038/Onc.2011.344 |
0.418 |
|
| 2012 |
Mack SC, Witt H, Shih D, Zuyderduyn S, Dubuc AM, Koster J, Northcott PA, Bertrand KC, Lau L, Kongkham PN, Wu X, Garzia L, Roberts SS, Massimi L, Meter TV, et al. Abstract 1428: A CpG island methylator phenotype defines a clinically aggressive subgroup of posterior fossa ependymoma Cancer Research. 72: 1428-1428. DOI: 10.1158/1538-7445.Am2012-1428 |
0.368 |
|
| 2011 |
De Sousa E Melo F, Colak S, Buikhuisen J, Koster J, Cameron K, De Jong JH, Tuynman JB, Prasetyanti PR, Fessler E, Van Den Bergh SP, Rodermond H, Dekker E, Van Der Loos CM, Pals ST, Van De Vijver MJ, et al. Methylation of cancer-stem-cell-associated wnt target genes predicts poor prognosis in colorectal cancer patients Cell Stem Cell. 9: 476-485. PMID 22056143 DOI: 10.1016/J.Stem.2011.10.008 |
0.416 |
|
| 2011 |
Bunt J, Hasselt NE, Zwijnenburg DA, Koster J, Versteeg R, Kool M. Joint binding of OTX2 and MYC in promotor regions is associated with high gene expression in medulloblastoma. Plos One. 6: e26058. PMID 22016811 DOI: 10.1371/Journal.Pone.0026058 |
0.337 |
|
| 2011 |
Lamers F, van der Ploeg I, Schild L, Ebus ME, Koster J, Hansen BR, Koch T, Versteeg R, Caron HN, Molenaar JJ. Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. Endocrine-Related Cancer. 18: 657-68. PMID 21859926 DOI: 10.1530/Erc-11-0207 |
0.354 |
|
| 2011 |
Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, van Sluis P, Molenaar J, Versteeg R, Stallings RL. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Molecular Carcinogenesis. 50: 403-11. PMID 21557326 DOI: 10.1002/Mc.20722 |
0.435 |
|
| 2011 |
Buckley PG, Das S, Bryan K, Watters KM, Alcock L, Koster J, Versteeg R, Stallings RL. Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions. International Journal of Cancer. 128: 2296-305. PMID 20669225 DOI: 10.1002/Ijc.25584 |
0.403 |
|
| 2010 |
Bunt J, De Haas TG, Hasselt NE, Zwijnenburg DA, Koster J, Versteeg R, Kool M. Regulation of cell cycle genes and induction of senescence by overexpression of OTX2 in medulloblastoma cell lines Molecular Cancer Research. 8: 1344-1357. PMID 21047732 DOI: 10.1158/1541-7786.Mcr-09-0546 |
0.421 |
|
| 2010 |
Hölzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H, Nijkamp W, Xie J, Callens T, Asgharzadeh S, Seeger RC, Messiaen L, Versteeg R, Bernards R. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell. 142: 218-29. PMID 20655465 DOI: 10.1016/J.Cell.2010.06.004 |
0.325 |
|
| 2010 |
Borsics T, Lundberg E, Geerts D, Koomoa DL, Koster J, Wester K, Bachmann AS. Subcellular distribution and expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in malignant glioma: Influence on cell survival and migration. Cancer Science. 101: 1624-31. PMID 20412121 DOI: 10.1111/J.1349-7006.2010.01570.X |
0.4 |
|
| 2010 |
Verissimo CS, Molenaar JJ, Meerman J, Puigvert JC, Lamers F, Koster J, Danen EHJ, Van De Water B, Versteeg R, Fitzsimons CP, Vreugdenhil E. Silencing of the microtubule-associated proteins doublecortin-like and doublecortin-like kinase-long induces apoptosis in neuroblastoma cells Endocrine-Related Cancer. 17: 399-414. PMID 20228126 DOI: 10.1677/Erc-09-0301 |
0.386 |
|
| 2010 |
Reinartz A, Ehling J, Franz S, Simon V, Bravo IG, Tessmer C, Zentgraf H, Lyer S, Schneider U, Köster J, Raupach K, Kämmerer E, Klaus C, Tischendorf JJ, Kopitz J, et al. Small intestinal mucosa expression of putative chaperone fls485. Bmc Gastroenterology. 10: 27. PMID 20205943 DOI: 10.1186/1471-230X-10-27 |
0.352 |
|
| 2010 |
Molenaar JJ, Ebus ME, Koster J, Santo E, Geerts D, Versteeg R, Caron HN. Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells. Oncogene. 29: 2739-45. PMID 20154722 DOI: 10.1038/Onc.2010.21 |
0.327 |
|
| 2010 |
Geerts D, Koster J, Albert D, Koomoa DL, Feith DJ, Pegg AE, Volckmann R, Caron H, Versteeg R, Bachmann AS. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. International Journal of Cancer. 126: 2012-24. PMID 19960435 DOI: 10.1002/Ijc.25074 |
0.415 |
|
| 2010 |
Revet I, Huizenga G, Koster J, Volckmann R, van Sluis P, Versteeg R, Geerts D. MSX1 induces the Wnt pathway antagonist genes DKK1, DKK2, DKK3, and SFRP1 in neuroblastoma cells, but does not block Wnt3 and Wnt5A signalling to DVL3 Cancer Letters. 289: 195-207. PMID 19815336 DOI: 10.1016/J.Canlet.2009.08.019 |
0.402 |
|
| 2010 |
Hölzel M, Huang S, Koster J, Ora I, Lakeman A, Caron HN, Callens T, Xie J, Nijkamp W, Asgharzadeh S, Seeger RC, Messiaen L, Versteeg R, Bernards R. Abstract A30: NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcme10-A30 |
0.32 |
|
| 2009 |
Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, Valentijn LJ, Westerhout EM, Versteeg R, Caron HN. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 106: 12968-73. PMID 19525400 DOI: 10.1073/Pnas.0901418106 |
0.435 |
|
| 2009 |
Cimmino F, Schulte JH, Zollo M, Koster J, Versteeg R, Iolascon A, Eggert A, Schramm A. Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness Oncogene. 28: 2015-2023. PMID 19363525 DOI: 10.1038/Onc.2009.70 |
0.416 |
|
| 2009 |
Huang S, Laoukili J, Epping MT, Koster J, Hölzel M, Westerman BA, Nijkamp W, Hata A, Asgharzadeh S, Seeger RC, Versteeg R, Beijersbergen RL, Bernards R. ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell. 15: 328-40. PMID 19345331 DOI: 10.1016/J.Ccr.2009.02.023 |
0.337 |
|
| 2009 |
Missiaglia E, Selfe J, Hamdi M, Williamson D, Schaaf G, Fang C, Koster J, Summersgill B, Messahel B, Versteeg R, Pritchard-Jones K, Kool M, Shipley J. Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development. Genes, Chromosomes & Cancer. 48: 455-67. PMID 19235922 DOI: 10.1002/Gcc.20655 |
0.42 |
|
| 2009 |
Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, Ora I, Pajtler K, Klein-Hitpass L, Kuhfittig-Kulle S, Metzger E, Schüle R, Eggert A, Buettner R, Kirfel J. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Research. 69: 2065-71. PMID 19223552 DOI: 10.1158/0008-5472.Can-08-1735 |
0.366 |
|
| 2009 |
Schulte JH, Pentek F, Hartmann W, Schramm A, Friedrichs N, Øra I, Koster J, Versteeg R, Kirfel J, Buettner R, Eggert A. The low-affinity neurotrophin receptor, p75, is upregulated in ganglioneuroblastoma/ganglioneuroma and reduces tumorigenicity of neuroblastoma cells in vivo International Journal of Cancer. 124: 2488-2494. PMID 19142969 DOI: 10.1002/Ijc.24204 |
0.392 |
|
| 2008 |
Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, Meeteren NS, Caron HN, Cloos J, Mrsić A, Ylstra B, Grajkowska W, Hartmann W, Pietsch T, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. Plos One. 3: e3088. PMID 18769486 DOI: 10.1371/Journal.Pone.0003088 |
0.371 |
|
| 2008 |
Molenaar JJ, Ebus ME, Koster J, van Sluis P, van Noesel CJ, Versteeg R, Caron HN. Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Research. 68: 2599-609. PMID 18413728 DOI: 10.1158/0008-5472.Can-07-5032 |
0.376 |
|
| 2008 |
Hatzis P, van der Flier LG, van Driel MA, Guryev V, Nielsen F, Denissov S, Nijman IJ, Koster J, Santo EE, Welboren W, Versteeg R, Cuppen E, van de Wetering M, Clevers H, Stunnenberg HG. Genome-wide pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cells. Molecular and Cellular Biology. 28: 2732-44. PMID 18268006 DOI: 10.1128/Mcb.02175-07 |
0.362 |
|
| 2008 |
Revet I, Huizenga G, Chan A, Koster J, Volckmann R, van Sluis P, Øra I, Versteeg R, Geerts D. The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Delta-Notch pathway in neuroblastoma Experimental Cell Research. 314: 707-719. PMID 18201699 DOI: 10.1016/J.Yexcr.2007.12.008 |
0.399 |
|
| 2008 |
Merks JH, Ozgen HM, Koster J, Zwinderman AH, Caron HN, Hennekam RC. Prevalence and patterns of morphological abnormalities in patients with childhood cancer. Jama. 299: 61-9. PMID 18167407 DOI: 10.1001/Jama.2007.66 |
0.318 |
|
| 2008 |
Koppen A, Ait-Aissa R, Koster J, Øra I, Bras J, Van Sluis PG, Caron H, Versteeg R, Valentijn LJ. Dickkopf-3 expression is a marker for neuroblasts tumor maturation and is down-regulated by MYCN International Journal of Cancer. 122: 1455-1464. PMID 18059033 DOI: 10.1002/Ijc.23180 |
0.434 |
|
| 2007 |
Geerts D, Wallick CJ, Koomoa DLT, Koster J, Versteeg R, Go RCV, Bachmann AS. Expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in neuroblastoma: Correlation with clinical features, cellular localization, and cerulenin-mediated apoptosis regulation Clinical Cancer Research. 13: 6312-6319. PMID 17975142 DOI: 10.1158/1078-0432.Ccr-07-0829 |
0.411 |
|
| 2007 |
Koppen A, Ait-Aissa R, Koster J, van Sluis PG, Ora I, Caron HN, Volckmann R, Versteeg R, Valentijn LJ. Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma. European Journal of Cancer (Oxford, England : 1990). 43: 2413-22. PMID 17826980 DOI: 10.1016/J.Ejca.2007.07.024 |
0.394 |
|
| 2007 |
Gierman HJ, Indemans MH, Koster J, Goetze S, Seppen J, Geerts D, van Driel R, Versteeg R. Domain-wide regulation of gene expression in the human genome. Genome Research. 17: 1286-95. PMID 17693573 DOI: 10.1101/Gr.6276007 |
0.335 |
|
| 2007 |
Koppen A, Ait-Aissa R, Hopman S, Koster J, Haneveld F, Versteeg R, Valentijn LJ. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation Cancer Letters. 256: 218-228. PMID 17643814 DOI: 10.1016/J.Canlet.2007.06.011 |
0.42 |
|
| 2007 |
Goetze S, Mateos-Langerak J, Gierman HJ, de Leeuw W, Giromus O, Indemans MH, Koster J, Ondrej V, Versteeg R, van Driel R. The three-dimensional structure of human interphase chromosomes is related to the transcriptome map. Molecular and Cellular Biology. 27: 4475-87. PMID 17420274 DOI: 10.1128/Mcb.00208-07 |
0.315 |
|
| 2004 |
Fontao L, Tasanen K, Huber M, Hohl D, Koster J, Bruckner-Tuderman L, Sonnenberg A, Borradori L. Molecular consequences of deletion of the cytoplasmic domain of bullous pemphigoid 180 in a patient with predominant features of epidermolysis bullosa simplex. The Journal of Investigative Dermatology. 122: 65-72. PMID 14962091 DOI: 10.1046/J.0022-202X.2003.22125.X |
0.301 |
|
| Show low-probability matches. |